Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

fwiw, here are the upcoming catalysts that are on my radar:

1) Ponatinib early approval-dec/jan (positive impact on revenue/cashflow)
2) Broad 2nd-line label(positive impact on revenue/competitive position)
3) Successful US ponatinib launch = upside surprise on sales/sales/sales
4) AP113 P1 read-out (ASCO?)
5) EMA approval and launch
6) AP113 registration trial (2nd-line ALK+ NSCLC)
7) EPIC Trial initial read-out
8) GIST or other pona registration trial

Of these, #3 is the most important in terms of pps (fwiw, a new compound won't even move the needle)